Wirtschaftsverband Chemie Pharma Life Sciences

Our members are searching for solutions against the coronavirus

Our industries support the coronavirus measures taken by the Federal Council, even though these will have a drastic effect on the economy. The members of scienceindustries are providers of solutions in these trying times for Switzerland and the world. They carry out research and work at full speed to develop new test procedures, vaccinations, medication and protective materials in the fight against the coronavirus. To achieve this goal, they must be able to continue producing at all costs.

07.04.2020

The research industries Chemistry Pharma Life Sciences are aware of their enormous social responsibility in the fight against the coronavirus/Covid-19 pandemic. The solidarity of our member companies with the Swiss population is tangible. Hopes are essentially pinned on medication that has already been approved for other diseases which might also work for Covid-19. This would be an immense help in fighting the pandemic, as it can take years to develop a new drug.

Research and development of medicines and tests are going ahead at full steam

The pharmaceutical and biotech company Gilead Sciences is researching its active ingredient Remdesivir as a possible drug against the Covid-19 virus. This drug is currently in the second clinical trial and was originally developed to fight the Ebola virus.

Pharmaceutical companies based in Basel are also working on developing medication against the virus. Novartis is pinning its hopes on its anti-malaria drug hydroxychloroquin. Preclinical trials and initial data from clinical trials show that the drug works against the coronavirus. Both Novartis and Bayer donated their medication used for the treatment and prevention of malaria to the US. Should the drug prove to be effective, both companies have declared their intention to donate millions of doses. Roche has started a clinical trial for its drug Actemra, which is hoped to be a suitable treatment for the virus as well.

Roche has also developed a highly automated corona test and ramped up its production to meet the enormous demand. An additional 1.4 million tests can be done in the short term in the USA. This will enormously expand the data basis. The resources that are freed up by the automated tests can now be dedicated to the treatment of patients.

Industry supplies healthcare facilities with protective materials and disinfectants

Syngenta has joined forces with Huntsman to deliver 50 tonnes of disinfectants hospitals and pharmacies. Lonza and Siegfried are producing and delivering huge volumes of disinfectants to hospitals and retirement homes, either free of charge or at cost price.

The SME HeiQ from Schlieren, a leader in textile innovation has developed a process for manufacturing antiviral and antimicrobial textiles. Masks and other textiles treated with this technology such as protection suits keep the virus at bay and are thus much more effective than regular protective materials.

Members of scienceindustries provide financial support

Members such as Givaudan, the manufacturer of aromas and fragrances and the two Basel-based companies Novartis and Roche are donating large sums to help Switzerland and the world get through the corona crisis. They support medical facilities, logistics, suppliers and customers.

scienceindustries members are system-relevant and have to continue production at all costs

In the fight against Covid-19, our Chemistry Pharma Life Sciences industries supply healthcare facilities such as hospitals and pharmacies with much-needed medication, protective equipment such as masks and disinfectants as quickly as possible. An example is caustic soda, a by-product in the production of chlorine by CABB, which is indispensable for the operation of water treatment plants and waste incinerations plants, and thus for hygiene.

As shown by these examples, the value chain of our industries is system-relevant and may therefore not under any circumstances be restricted. Production by our industries must without fail be secured at all times for reasons of health and economic policy - for our people and our country, today and in the future.


Close

Newsletter subscription

Quarterly Newsletter
Standpoints

 
 

Foreign trade statistics chemistry pharma life science

Further analyzes

Export Chemicals Pharma Life Sciences Switzerland by region

Further analyzes